Featured News Headlines
NVO Stock Update: Institutional Investment and Analyst Ratings
In the latest filings with the Securities and Exchange Commission (SEC), Baldwin Wealth Partners LLC MA significantly reduced its stake in Novo Nordisk A/S (NYSE:NVO) during the third quarter. The firm sold 148,569 shares, reducing its holdings by 82%, leaving it with 32,556 shares valued at approximately $1.81 million at the end of the reporting period.
Hedge Fund Activity in Novo Nordisk
Several other institutional investors adjusted their positions in Novo Nordisk during recent quarters. NewSquare Capital LLC increased its holdings by 174.1% in Q2, now holding 444 shares worth around $31,000 after adding 282 shares. Meanwhile, Mid American Wealth Advisory Group Inc. and State of Wyoming both initiated new positions in Novo Nordisk shares, valued at $37,000 and $38,000, respectively.
Additional activity included Maseco LLP, which acquired a new stake valued at $39,000, and Copeland Capital Management LLC, which increased its holdings by 47.3%, now holding 579 shares worth approximately $40,000. Overall, 11.54% of Novo Nordisk stock is owned by hedge funds and other institutional investors.
Recent Analyst Ratings
Research analysts have recently updated their outlooks on Novo Nordisk shares. Sanford C. Bernstein upgraded NVO from a “market perform” to an “outperform” rating on September 9. Morgan Stanley maintained an “underweight”rating with a $42 price target as of December 3, while Goldman Sachs lowered its target from $60 to $54 and kept a buy rating as of November 28.
Additionally, Rothschild Redb upgraded NVO from “hold” to “strong-buy” on September 16. HSBC reaffirmed a “hold” rating with a $54 price target on December 10. According to MarketBeat.com, the stock currently holds a consensus “Hold” rating with a consensus target price of $53.33. In total, one analyst rated the stock as Strong Buy, six as Buy, eleven as Hold, and four as Sell.
Novo Nordisk Stock Performance
On Monday, NVO opened at $48.10. Over the past year, the stock has ranged from a low of $43.08 to a high of $93.80. Novo Nordisk’s market capitalization stands at $214.76 billion, with a P/E ratio of 13.98 and a beta of 0.67. The company’s current ratio is 0.78, quick ratio 0.57, and debt-to-equity ratio 0.52. Technical indicators show the 50-day simple moving average at $49.84 and the 200-day simple moving average at $57.49.
Recent Earnings Report
Novo Nordisk reported its latest quarterly earnings on November 5. The company posted $1.02 earnings per share (EPS), exceeding analysts’ consensus estimate of $0.77 by $0.25. Quarterly revenue reached $11.79 billion, slightly below the consensus estimate of $11.98 billion. Financial ratios show a return on equity of 73.50% and a net margin of 32.76%. On average, analysts forecast 3.84 EPS for the current fiscal year.
Market Implications
The data highlights active adjustments by institutional investors and the ongoing attention of analysts toward Novo Nordisk. As Baldwin Wealth Partners LLC MA reduced its holdings, other firms such as NewSquare Capital LLC and Copeland Capital Management LLC increased theirs, reflecting diverse institutional strategies.
Analyst movements indicate a mix of optimism and caution. While firms like Rothschild Redb view NVO as a strong-buy, others like Morgan Stanley maintain a more conservative approach with an underweight rating. The consensus hold rating reflects a general market expectation of moderate growth and stability in Novo Nordisk shares.
